Lexitas
Durham, North Carolina, 27703, United States
NCT Number: NCT04556838
This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Durham, North Carolina, 27703, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
VVN001 Ophthalmic Solution 1%
VVN001 Ophthalmic Solution 5%
VVN001 Ophthalmic Solution Vehicle
Time frame: Day 84
Mean change from baseline in Inferior corneal fluorescein staining. Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -4 to +4.
Time frame: Day 84
Mean change from baseline in total corneal fluorescein staining Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -20 to +20.
Time frame: Day 84
Mean change from baseline in temporal regional corneal fluorescein staining. Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -4 to +4.
Time frame: Day 84
Mean Change in Eye Dryness VAS. Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -100 to +100..
VivaVision Biotech, Inc
Industry
A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 Compared to Vehicle in Subjects With Dry Eye Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07089511
Dry Eye, Dry Eye Syndromes
Milan, Italy
View Trial DetailsNCT06346340
Dry Eye, Dry Eye Syndromes
Laguna Hills, California, United States
View Trial DetailsNCT07675460
Acne Cystic, Choroidal Thickness
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT04418999
Allergy, Corneal Diseases
Chicago, Illinois, United States
View Trial Details